GlobeNewswire·Jun 1, 2026, 4:15 PM ET

Praxis Precision Medicines Provides Vormatrigine Program Update

The Phase 2/3 POWER1 study for vormatrigine in highly refractory focal onset seizure patients failed to meet its primary endpoint of percent change in monthly seizure frequency.
The study met the secondary endpoint of a 50% response rate, with seizure reduction being more pronounced during the second half of the trial on the higher 30 mg dose.
Vormatrigine demonstrated a generally well-tolerated safety profile, with adverse event-related discontinuations remaining below 10%.
Approximately 90% of patients in the vormatrigine arm transitioned to and remain in the open label extension study.
Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program & determine potential modifications.